The European Union health technology assessment system has produced its first public joint clinical assessment report, moving the new process from preparatory guidance into visible operational use. Although the report concerns tovorafenib, the access-relevant development is the publication of the first clinical assessment package that national authorities can draw on during pricing and reimbursement work.
The European Commission published the Joint clinical assessment report on tovorafenib (Ojemda) on 9 June 2026. The package includes the joint clinical assessment report, a summary report, the health technology developer dossier and an annex covering the factual accuracy check and the assessors’ response.
The report had been endorsed by the Member State Coordination Group on Health Technology Assessment (HTACG) on 30 April 2026. The European Commission completed its procedural review on 19 May 2026, allowing publication of the first full output under the EU Health Technology Assessment Regulation.
The publication follows earlier implementation material from HTACG and the Commission, including guidance on report publication, dossier transparency, confidentiality and methodological procedure. It also follows the April developer webinar, where the Commission reported that 16 medicinal-product joint clinical assessments had already been initiated.
The new material gives companies, national HTA bodies and access teams the first complete example of how the public EU assessment record is being assembled. It shows the format of the report, the structure of the developer dossier and the way the assessment handles patient input, expert contribution, uncertainty and evidence gaps.
The summary report also shows how the assessors present conclusions across the agreed assessment scopes. The treatment of the PICO questions is relevant because it indicates how differences between Member State information needs are being carried through into the public report, rather than resolved into a single composite clinical question.
The first public report makes the shared clinical record visible at the point where EU assessment begins to feed into national processes. Economic assessment, value judgement, price negotiation and reimbursement decisions remain national responsibilities, but the clinical evidence base will now increasingly start from a common EU document. Developers can now see the practical format and evidentiary expectations that may shape later national HTA files.
Source: European Commission
Link: Joint clinical assessment report on tovorafenib (Ojemda)
Date: 9 June 2026
